New Releases from NCBI BookshelfBaricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal).​Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal).

Post Content

​ 

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top